United States: A Cautiously Optimistic Diagnosis For Patent Eligibility

For companies in the life sciences industry, the scope of patent eligibility continued its apparently inexorable contraction in 2017. Inventions deemed ineligible for patenting included methods for assessing cardiovascular risk based on myeloperoxidase levels — despite the existence of prior art methods that failed to preserve a correlation;1 methods for diagnosing a new subtype of myasthenia gravis — despite the methods' practical application of man-made reagents;2 and dietary alanine supplements and their use for increasing human muscle tissue strength — despite the non-natural physiological effects of such supplementation.3

But in the first months of 2018, the Federal Circuit has exhibited a more generous approach to both steps one and two of the patent eligibility analysis. Moreover, the court's acknowledgement that patent eligibility, while ultimately a question of law, may rest on factual issues improves the likelihood of surviving early dismissal motions. To be clear, congressional action remains necessary to ensure that valuable inventions in the life sciences industry receive crucial patent protection. Since no such action seems imminent, this article discusses the recent developments from the Federal Circuit, and explores how these developments offer potential routes for navigating Section 101 challenges in the courts.

The Two-Step Test

As elaborated by the U.S. Supreme Court in Mayo and Alice, the eligibility analysis consists of two steps.4 The challenged claim is first examined to determine if it is "directed to" ineligible subject matter, i.e., a law of nature, a natural phenomenon, or an abstract idea. If it is not, then the claim is patentable under Section 101 and the analysis ends. But if the claim is found directed to ineligible subject matter — usually a law of nature or natural phenomenon for inventions in the life sciences — then the analysis proceeds to step two to determine whether the claim elements, alone or in an ordered combination, contain some other inventive concept, beyond mere "well-understood, routine, conventional activity." This two-step framework is said to ensure that a claim directed to, say, a law of nature does not rely solely on that natural law to establish patent eligibility.

Surviving Step One

In Vanda Pharmaceuticals Inc. v. West-Ward Pharmaceuticals Int'l Ltd.,5 the Federal Circuit affirmed a district court's finding that claims to a personalized method of treatment are patent eligible. Although the district court found patent eligibility at step two, the majority opinion — with Chief Judge Sharon Prost dissenting — concluded that the claims are not drawn to patent ineligible subject matter in the first instance. And in so doing, the decision strongly suggests that, where appropriately drafted, method of treatment claims directed to the application of a drug to a particular disease are generally patent eligible.

Vanda's patent describes an improved method of treating schizophrenia with iloperidone, wherein the drug dosage administered is determined by the patient's genotype. Following its administration, iloperidone is metabolized by the enzyme cytochrome P450 2D6, encoded by the CYP2D6 gene. Certain mutations in that gene, however, impair iloperidone clearance, thereby effectively increasing the concentration of iloperidone in the patient. Such impaired drug clearance can prove dangerous given that iloperidone has been observed to prolong the QT interval, thus increasing the risk of fatal cardiac arrhythmias. In order to decrease the risk of QT prolongation, the claimed method thus requires genotyping a schizophrenic patient to determine if that individual possesses "a CYP2D6 poor metabolizer genotype," and administering iloperidone either at a dosage of 12 mg/day or less if the patient is a poor metabolizer or at a dosage of more than 12 mg/day if the patient is not a poor metabolizer.

While acknowledging that the claimed invention rests on the inventors' discovery of the natural relationship between iloperidone, CYP2D6 metabolism, and QT prolongation, the majority opinion concludes that the claims are "directed to" an application of that natural relationship, and not the natural relationship itself. According to the majority, that application is a particularized method of disease treatment: "At bottom, the claims here are directed to a specific method of treatment for specific patients using a specific compound at specific doses to achieve a specific outcome." By contrast, the majority differentiates the claims at issue in Mayo — drawn to "optimizing therapeutic efficacy" by determining the levels of a thiopurine drug in a patient's blood and specifying thresholds indicative of a need to increase or decrease the thiopurine's dosage — as instead "directed to a diagnostic method" given the absence of any requirement that drug dosage be adjusted in response to the diagnostic finding.

The Vanda decision offers patent eligibility relief not only to life sciences companies developing new drugs and new methods for disease treatment, but also to those companies developing diagnostic tests. Specifically, by adding particularized treatment steps, it may be possible to reclaim patent eligibility for diagnostic claims. Care is required in drafting such claims, however, to minimize issues of divided infringement, as diagnosis and treatment steps may be performed by separate entities.6

Surviving Step Two

In Exergen Corp. v. Kaz USA Inc.,7 the Federal Circuit similarly affirmed a district court's finding that the claims at issue were patent eligible, but at step two rather than step one. The decision, from which Judge Todd Hughes dissented, suggests that it may be possible to establish patent eligibility in the life sciences for claims directed to a combination of routine elements specifically adapted to a new purpose.

Exergen's founder developed a noninvasive thermometer capable of determining core body temperature. Specifically, he discovered the precise mathematical algorithm that allows core body temperature to be calculated from two more easily measured temperatures: first, the temperature of the skin above the temporal artery in the forehead and second, ambient temperature. Exergen's founder further realized that even though the location of the temporal artery varies among individuals, the temperature above it could be easily detected by laterally scanning the forehead and identifying the peak reading. Exergen ultimately obtained claims to both a "body temperature detector" and a "method of detecting human body temperature," with additional claim elements requiring that the device or method used employ lateral scanning of the forehead, obtain at least three temperature readings per second, and identify the peak temperature. Following a jury trial, the district court concluded that this claimed combination is patent eligible.

On appeal, the majority opinion found that the claims are directed to the natural phenomenon of core body temperature, and so summarily proceeded to step two of the patent eligibility analysis. The conventionality of the physical component of Exergen's claims — i.e., the thermometer itself — was largely, if not entirely, undisputed given that Exergen had previously marketed the DermaTemp product, a device that could scan surface temperature, take ten temperature readings per second, and identify the peak temperature scanned. DermaTemp, however, was not used to determine core body temperature as required by the claims at issue, but rather to identify variations in skin temperature as an aid to the diagnosis of injury or disease. This distinction allowed the majority opinion to base patent eligibility on the unconventionality of the method of temperature measurement encompassed by Exergen's claims:

Following years and millions of dollars of testing and development, the inventor determined for the first time the coefficient representing the relationship between temporal-arterial temperature and core body temperature and incorporated that discovery into an unconventional method of temperature measurement.

In reaching this conclusion, the majority also emphasized the deference owing to the district court as factfinder, as further explored in the next section.

Although brief, the majority's analysis suggests that when viewed as a whole, a combination of conventional elements may be patent eligible when put to a new purpose. Exergen effectively adapted old technology by incorporating electronics capable of running the core temperature algorithm discovered by its founder, and then using that device in a particular way — to laterally scan the human forehead. The same is true of many diagnostic inventions, which often adapt known methods to measure a natural phenomenon. The majority decision in Exergen suggests that another path to patent eligibility for such diagnostics lies in claiming both the different application of any conventional methods used in the invention, as well as any nonroutine modifications required to make those methods work.

Surviving Early Motions to Dismiss

Exergen appears to have benefited from the fact that its case proceeded all the way to a jury trial. After hearing extensive testimony and evidence of novelty and nonobviousness, and receiving a jury verdict in the patentee's favor, a district court will likely find it more difficult to nonetheless conclude that this same invention consists purely of well-understood, routine, conventional elements. Nor are the facts that the jury must necessarily find in reaching such a verdict consistent with a conclusion of patent ineligibility at step two. Surviving early Section 101 challenges thus significantly increases the odds of later prevailing on patent eligibility.

Fortunately, the Federal Circuit's recent procedural clarifications should make it easier for patentees to survive early Section 101 challenges. In a series of three decisions,8 the appellate court made explicit that while patent eligibility under Section 101 is ultimately an issue of law, step two nonetheless implicates an underlying question of fact. Specifically, whether a technology was well-understood, routine and conventional to a skilled artisan at the time of the patent is a factual determination.

This is a crucial development for those facing a motion pursuant to Rule 12(b)(6), as dismissal is now inappropriate so long as the pleadings include concrete allegations that the elements of the claims, individually or together, did not constitute well-understood, routine or conventional activity. Of course, such allegations must include sufficient factual detail to be plausible, and need not be accepted by a court as true if contradicted by the patent specification itself.9 The latter may prove challenging for some patentees if their specification describes the claim elements as well-known to those of skill in the art. This prosecution shortcut is, unfortunately, not uncommon in an industry subject to increasingly stringent written description and enablement requirements.10 Faced with that scenario, a patentee's best approach — where possible — may be to include allegations explaining why application of the admittedly well-known methods in the context of the claimed invention was not well-understood, routine, or conventional.

Conclusion

Although the Federal Circuit's recent eligibility decisions bring some hope to patent owners, they are not a cure for what ails the life sciences industry. Judicial decisions are not always lasting, as evidenced by the changes wrought by Mayo and Alice themselves. Indeed, the Federal Circuit has refused to grant precedential status to its Exergen decision,11 and petitions for en banc rehearing have been filed requesting that the full court consider whether patent eligibility is a pure question of law with no underlying factual issues.12 Perhaps the new leadership at the U.S. Patent and Trademark office will spur congressional movement toward a permanent legislative solution that accounts for the needs of the life sciences industry. But in the meantime, the toeholds described in this article may provide patent owners with strategic prosecution and litigation options as they navigate Section 101.

Originally published in Law360 on May 8, 2018.

Footnotes

1 Cleveland Clinic Found. v. True Health Diagnostics LLC, 859 F.3d 1352 (Fed. Cir. 2017), petition for cert. filed (U.S. Jan. 16, 2018) (No. 17-997).

2 Athena Diagnostics, Inc. v. Mayo Collaborative Servs., LLC, __ F. Supp. 3d __, 2017 WL 3336275 (D. Mass. Aug. 4, 2017), appeal docketed, No. 2017-2508 (Fed. Cir. Sept. 5, 2018).

3 Natural Alternatives Int'l, Inc. v. Creative Compounds, LLC, 2017 WL 3877808 (S.D. Cal. Sept. 5, 2017), appeal docketed, No. 2018-1295 (Fed. Cir. Dec. 12, 2017).

4 Mayo Collaborative Svcs. v. Prometheus Labs., Inc., 132 S. Ct. 1289 (2012); Alice Corp. Pty. Ltd. v. CLS Bank Int'l, 134 S. Ct. 2347 (2014).

5 Vanda Pharm., Inc. v. West-Ward Pharm. Int'l Ltd., __ F.3d __, 2018 WL 1770273 (Fed. Cir. 2018).

6 Compare, e.g., Cleveland Clinic Found. v. True Health Diagnostics LLC, 859 F.3d 1352 (Fed. Cir. 2017) with Eli Lilly & Co. v. Teva Parenteral Medicines, Inc., 845 F.3d 1357 (Fed. Cir. 2017).

7 Exergen Corp. v. Kaz USA, Inc., __ F. App'x __, 2018 WL 1193529 (Fed. Cir. 2018)

8 Berkheimer v. HP Inc., 881 F.3d 1360 (Fed. Cir. 2018); Aatrix Software, Inc. v. Green Shades Software, Inc., 882 F.3d 1121 (Fed. Cir. 2018); and Exergen, 2018 WL 1193529.

9 Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009) ("To survive a motion to dismiss, a complaint must contain sufficient factual matter, accepted as true, to 'state a claim to relief that is plausible on its face.'" (quoting Bell Atl. Corp v. Twombly, 550 U.S. 544, 570 (2007))); Secured Mail Solutions LLC v. Universal Wilde, Inc., 873 F.3d 905, 913 (Fed. Cir. 2017) ("In ruling on a 12(b)(6) motion, a court need not 'accept as true allegations that contradict matters properly subject to judicial notice or by exhibit,' such as the claims and the patent specification." (quoting Anderson v. Kimberly-Clark Corp., 570 F. App'x 927, 931 (Fed. Cir. 2014))).

10 In Cleveland Clinic, for example, the specification indicated that the claimed method could utilize "any of a variety of standard methods known in the art." 859 F.3d at 1355. Similarly, in Athena Diagnostics, the specification described the procedures used by the inventors as "standard techniques in the art." 2017 WL 3336275, at *5.

11 Order, Exergen Corp. v. Kaz USA, Inc., No. 16-2315 (Fed. Cir. Mar. 16, 2018), Dkt. No. 70.

12 Appellee HP Inc.'s Petition for Rehearing En Banc, Berkheimer v. HP Inc., No. 17-1437 (Fed. Cir.), Dkt. No. 56; Appellee Grade Shades Software, Inc.'s Petition for Rehearing En Banc, Aatrix Software, Inc. v. Green Shades Software, Inc., No. 17-1452 (Fed. Cir.), Dkt. No. 37.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Events from this Firm
21 Jan 2019, Speaking Engagement, California, United States

Now entering its fifth year, the Pocket Gamer Connects events series has grown to become the biggest and most influential mobile games conference in the west as well as th​e biggest games event overall in the UK and Helsinki.

8 Mar 2019, Conference, Austin, United States

Join the world’s largest gathering of creative professionals at the 2019 SXSW Conference & Festivals in Austin, Texas from March 8-17.

Similar Articles
Relevancy Powered by MondaqAI
Foley & Lardner
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Foley & Lardner
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions